Table 3

Proportion of patients with LDAS* or remission at baseline and at Month 6 for second line abatacept stratified by 1 or ≥2 prior anti-TNF agent
Measure Remission at month 6 LDAS* at month 6
N Percent (95% CI) N Percent (95% CI)
One previous anti-TNF
DAS28 (ESR) 245 15.9 (11.3, 20.5) 245 29.8 (24.1, 35.5)
DAS28 (CRP) 57 22.8 (11.9, 33.7) 57 42.1 (29.3, 54.9)
CDAI 289 5.2 (2.6, 7.7) 289 35.6 (30.1, 41.2)
≥2 previous anti-TNFs
DAS28 (ESR) 234 12.8 (8.5, 17.1) 234 25.6 (20.0, 31.2)
DAS28 (CRP) 75 17.3 (8.8, 25.9) 75 33.3 (22.7, 44.0)
CDAI 286 4.9 (2.4, 7.4) 286 28.3 (23.1, 33.5)

*LDAS includes patients in remission (DAS remission: <2.6; CDAI remission: ≤2.8).

CDAI, Clinical Disease Activity Index; DAS, Disease Activity Score; LDAS, Low Disease Activity Score (≤3.2 for DAS and ≤10 for CDAI).

Nüßlein et al.

Nüßlein et al. BMC Musculoskeletal Disorders 2014 15:14   doi:10.1186/1471-2474-15-14

Open Data